SFTPA1 and metabolic dysfunction-associated steatotic liver disease: However, results from this study provide evidence that SPA promotes lipid accumulation, hepatic inflammation, and fibrosis by increasing fatty acid uptake and activating stellate cells in MASLD, suggesting that SPA inhibition may be a potential therapeutic strategy to treat MASLD.